Skip to search formSkip to main contentSkip to account menu

sonidegib

Known as: (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-, ERISMODEGIB, N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide 
An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent Terminologysonidegib 200 MG Oral Capsule [Odomzo]

Broader (1)

Smoothened Antagonist LDE225

Narrower (1)

sonidegib phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation
Somatic activating mutations of smoothened (SMO), a component of the embryonic sonic hedgehog (SHH) signaling pathway, are found… 
2018
2018
Effects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT.
9573Background: Sonidegib is a hedgehog pathway inhibitor (HPI) approved for the treatment of locally advanced basal cell… 
2018
2018
Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on…
Background : although azacitidine (AZA) is an established frontline therapy for HR-MDS, approximately 40% of the patients fail… 
Review
2017
Review
2017
Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma
Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits… 
2016
2016
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
AIMS This study aimed to evaluate the impact of esomeprazole on the pharmacokinetics of sonidegib. METHODS This Phase I study… 
2016
2016
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
371 Background: Sonidegib (LDE225) is a potent, selective, and orally bioavailable inhibitor of smoothened receptor that… 
Review
2016
Review
2016
Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice
Purpose of review We summarize the concept of a locally advanced basal cell carcinoma (laBCC) and present the current consensus… 
2016
2016
Exposure‐Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors
Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway‐dependent tumors, and has recently… 
Review
2015
Review
2015
Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
Background: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has been approved for the treatment of disease-related splenomegaly… 
2014
2014
Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
Background: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has been shown to effectively reduce splenomegaly, manage… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)